Ketamine molecule:

Image from PubChem

Ketamine Clinical Trials


Initiating Ketamine in Acutely Suicidal Patients in the Emergency Department


To see complete record on clinicaltrials.gov, please visit this link

Id: NCT04260607

Organisation Name: Naval Medical Center Camp Lejeune

Overal Status: Enrolling by invitation

Start Date: January 14, 2020

Last Update: February 7, 2020

Lead Sponsor: Naval Medical Center Camp Lejeune

Brief Summary: Current treatment for acutely suicidal patients are limited to hospitalization, psychotherapy, electro-convulsant therapy, or a combination of the aforementioned. However, this has added to the national boarding problem. Long term pharmacologic treatment for suicidal behaviors and mood stabilization has been studied in specific populations. In these populations, the decreases in suicidal ideation results from stabilization of the underlying psychiatric illness. Ketamine is most commonly used as an anesthetic with analgesic properties. It has been used off-label for pain management, procedural sedation, status epilepticus, and treatment resistant depression. It has been safely administered intravenously and well tolerated for chronic Post Traumatic Stress Disorder. It increases norepinephrine, dopamine, and serotonin through adrenergic neuron stimulation and prevention of catecholamine uptake. There is a strong corollary between stress and the development of depression and suicidal behaviors. It is proposed that the use of low dose intravenous ketamine may have benefit on the suicidal ideation of patients presenting to the Emergency Department.

Conditions:
  • Suicide
  • Suicide Threat
  • Depression Severe


Total execution time in seconds: 0.16359996795654